Citation: Gu Yiyu, Lü Xiaoqing, Ma Xiaodong, Zhang Haojian, Ji Yuanyuan, Ding Wanjing, Shen Li. Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-Based Hydroxamic Acids as PI3K and HDAC Dual Targeting Inhibitors[J]. Chinese Journal of Organic Chemistry, ;2020, 40(1): 95-107. doi: 10.6023/cjoc201908021 shu

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-Based Hydroxamic Acids as PI3K and HDAC Dual Targeting Inhibitors

a.
Ocean College, Zhejiang University, Zhoushan, Zhejiang 316021
b.
College of Medicine, Jiaxing University, Jiaxing, Zhejiang 314001
c.
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012

Corresponding author: Shen Li, shenli@zju.edu.cn
Received Date: 13 August 2019
Revised Date: 5 September 2019
Available Online: 18 January 2019
Fund Project: the Foundation for the Science and Technology Project of Zhoushan City 2018C81035the National Natural Science Foundation for Young Scientists of China 81402845Project supported by the National Natural Science Foundation for Young Scientists of China (No. 81402845) and the Foundation for the Science and Technology Project of Zhoushan City (No. 2018C81035)

Figures(4)

Polypharmacology has emerged as a promising approach to drug discovery, especially antitumor drug. This study reports the design, synthesis, and biological evaluation of novel phosphatidylinositol 3-kinases (PI3Ks) and histone deacetylases (HDACs) dual inhibitors on the basis of GSK2126458 under clinical evaluation and vorinostat approved. Among these hybrid molecules, GYB-4 and GYB-5 possessed potent inhibition against both PI3Kα (1.0 and 1.3 nmol/L, respectively) and HDAC1 (4.2 and 4.8 nmol/L, respectively). Antiproliferative assays with HCT116, PC3 and A2780 cell lines subsequently were performed. The structure-activity relationship study will guide to optimization of dual PI3K and HDAC inhibitors.
- phosphatidylinositol 3-kinases (PI3K),
- histone deacetylases (HDAC),
- dual targeting inhibitor,
- bioactivity
1. [1]
  Porta, C.; Paglino, C.; Mosca, A. Front Oncol. 2014, 4, 64.
2. [2]
  Pons-Tostivint, E.; Thibault, B.; Guillermet-Guibert, J. Trends Cancer 2017, 3, 454. doi: 10.1016/j.trecan.2017.04.002
3. [3]
  Nelson, C. M.; Chen, C. S. FEBS Lett. 2002, 514, 238. doi: 10.1016/S0014-5793(02)02370-0
4. [4]
  Okkenhaug, K.; Vanhaesebroeck, B. Nat. Rev. Immunol. 2003, 3, 317. doi: 10.1038/nri1056
5. [5]
  Cantley, L. C. Science 2002, 296, 1655. doi: 10.1126/science.296.5573.1655
6. [6]
  Ikenoue, T.; Kanai, F.; Hikiba, Y.; Obata, T.; Tanaka, Y.; Imamura, J.; Ohta, M.; Jazag, A.; Guleng, B.; Tateishi, K.; Asaoka, Y.; Matsumura, M.; Kawabe, T.; Omata, M. Cancer Res. 2005, 65, 4562. doi: 10.1158/0008-5472.CAN-04-4114
7. [7]
  Fruman, D. A.; Rommel, C. Nat. Rev. Drug Discovery 2014, 13, 140. doi: 10.1038/nrd4204
8. [8]
  West, A. C.; Johnstone, R. W. J. Clin. Invest. 2014, 124, 30. doi: 10.1172/JCI69738
9. [9]
  Polo, S. E.; Almouzni, G. Cancer Lett. 2005, 220, 1. doi: 10.1016/j.canlet.2004.08.024
10. [10]
  Vidanes, G. M.; Bonilla, C. Y.; Toczyski, D. P. Cell 2005, 121, 973. doi: 10.1016/j.cell.2005.06.013
11. [11]
  Friedrich, M.; Gerbeth, L.; Gerling, M.; Rosenthal, R.; Steiger, K.; Weidinger, C.; Keye, J.; Wu, H.; Schmidt, F.; Weichert, W.; Siegmund, B.; Glauben, R. Mucosal Immunol. 2019, 12, 656. doi: 10.1038/s41385-019-0135-7
12. [12]
  Yang, J.; Jin, X.; Yan, Y.-Q.; Shao, Y.-J.; Pan, Y.-Q.; Roberts, L. R.; Zhang, J.; Huang, H.-J.; Jiang, J.-T. Sci. Rep. 2017, 7, 43864. doi: 10.1038/srep43864
13. [13]
  Zhou, W.-Q.; Feng, X.-Y.; Han, H.; Guo, S.-C.; Wang, G.-D. Sci. Rep. 2016, 6, 28004. doi: 10.1038/srep28004
14. [14]
  Marks, P. A.; Breslow, R. Nat. Biotechnol. 2007, 25, 84. doi: 10.1038/nbt1272
15. [15]
  McKinsey, T. A. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 303. doi: 10.1146/annurev-pharmtox-010611-134712
16. [16]
  Xing, S.-F.; Nie, F.; Xu, Q.; Deng, Y.-X.; Li, W.; Yang, Z.-W.; Zhao, X.-Y.; Zhu, P.; Wang, X.-R.; Gao, Y.; He, Z.-Y. Lab. Invest. 2015, 95, 1105. doi: 10.1038/labinvest.2015.97
17. [17]
  Grant, S.; Easley, C.; Kirkpatrick, P. Nat. Rev. Drug Discovery 2007, 6, 21. doi: 10.1038/nrd2227
18. [18]
  Bertino, E. M.; Otterson, G. A. Expert Opin. Investig. Drugs 2011, 20, 1151. doi: 10.1517/13543784.2011.594437
19. [19]
  Poole, R. M. Drugs 2014, 74, 1543. doi: 10.1007/s40265-014-0275-8
20. [20]
  Garnock-Jones, K. P. Drugs 2015, 75, 695. doi: 10.1007/s40265-015-0388-8
21. [21]
  Ning, Z.-Q.; Li, Z.-B.; Newman, M. J.; Shan, S.; Wang, X.-H.; Pan, D.-S.; Zhang, J.; Dong, M.; Du, X.; Lu, X.-P. Cancer Chemother. Pharmacol. 2012, 69, 901. doi: 10.1007/s00280-011-1766-x
22. [22]
  Nervi, C.; De Marinis, E.; Codacci-Pisanelli, G. Clin. Epigenet. 2015, 7, 127. doi: 10.1186/s13148-015-0157-2
23. [23]
  Ozaki, K.; Kosugi, M.; Baba, N.; Fujio, K.; Sakamoto, T.; Kimura, S.; Tanimura, S.; Kohno, M. Biochem. Biophys. Res. Commun. 2010, 391, 1610. doi: 10.1016/j.bbrc.2009.12.086
24. [24]
  Yoshioka, T.; Yogosawa, S.; Yamada, T.; Kitawaki, J.; Sakai, T. Gynecol. Oncol. 2013, 129, 425. doi: 10.1016/j.ygyno.2013.02.008
25. [25]
  Ellis, L.; Ku, S. Y.; Ramakrishnan, S.; Lasorsa, E.; Azabdaftari, G.; Godoy, A.; Pili, R. Oncotarget 2013, 4, 2225.
26. [26]
  Rahmani, M.; Aust, M. M.; Benson, E. C.; Wallace, L.; Friedberg, J.; Grant, S. Clin. Cancer Res. 2014, 20, 4849. doi: 10.1158/1078-0432.CCR-14-0034
27. [27]
  Anighoro, A.; Bajorath, J.; Rastelli, G. J. Med. Chem. 2014, 57, 7874. doi: 10.1021/jm5006463
28. [28]
  Peters, J. U. J. Med. Chem. 2013, 56, 8955. doi: 10.1021/jm400856t
29. [29]
  Gupta, A. K.; Arshad, S.; Poulter, N. R. Hypertension 2010, 55, 399. doi: 10.1161/HYPERTENSIONAHA.109.139816
30. [30]
  Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. I.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C. M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. ACS Med. Chem.Lett. 2010, 1, 39. doi: 10.1021/ml900028r
31. [31]
  Lv, X.-Q.; Ying, H.-Z.; Ma, X.-D.; Qiu, N.; Wu, P.; Yang, B.; Hu, Y.-Z., Eur. J. Med. Chem. 2015, 99, 36. doi: 10.1016/j.ejmech.2015.05.025
32. [32]
  De Simone, A.; La Pietra, V.; Betari, N.; Petragnani, N.; Conte, M.; Daniele, S.; Pietrobono, D.; Martini, C.; Petralla, S.; Casadei, R.; Davani, L.; Frabetti, F.; Russomanno, P.; Novellino, E.; Montanari, S.; Tumiatti, V.; Ballerini, P.; Sarno, F.; Nebbioso, A.; Altucci, L.; Monti, B.; Andrisano, V.; Milelli, A. ACS Med. Chem. Lett. 2019, 10, 469. doi: 10.1021/acsmedchemlett.8b00507
33. [33]
  Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Nature 1999, 401, 188. doi: 10.1038/43710
34. [34]
  Morphy, R.; Rankovic, Z. J. Med. Chem. 2005, 48, 6523. doi: 10.1021/jm058225d
35. [35]
  Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457. doi: 10.1021/cr00039a007
36. [36]
  Andrianov, V.; Gailite, V.; Lola, D.; Loza, E.; Semenikhina, V.; Kalvinsh, I.; Finn, P.; Petersen, K. D.; Ritchie, J. W.; Khan, N.; Tumber, A.; Collins, L. S.; Vadlamudi, S. M.; Bjorkling, F.; Sehested, M. Eur. J. Med. Chem. 2009, 44, 1067. doi: 10.1016/j.ejmech.2008.06.020
37. [37]
  Lagger, G.; O'Carroll, D.; Rembold, M.; Khier, H.; Tischler, J.; Weitzer, G.; Schuettengruber, B.; Hauser, C.; Brunmeir, R.; Jenuwein, T.; Seiser, C. EMBO J. 2002, 21, 2672. doi: 10.1093/emboj/21.11.2672
38. [38]
  Raynaud, F. I.; Eccles, S. A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; De Haven Brandon, A.; Di Stefano, F.; Hayes, A.; Henley, A. T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A.; McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N. C.; Clarke, P. A.; Workman, P. Mol. Cancer Ther. 2009, 8, 1725. doi: 10.1158/1535-7163.MCT-08-1200
39. [39]
  Botta, C. B.; Cabri, W.; Cini, E.; De Cesare, L.; Fattorusso, C.; Giannini, G.; Persico, M.; Petrella, A.; Rondinelli, F.; Rodriquez, M.; Russo, A.; Taddei, M. J. Med. Chem. 2011, 54, 2165. doi: 10.1021/jm101373a
40. [40]
  Crawford, T. D.; Vartanian, S.; CÖté, A.; Bellon, S.; Duplessis, M.; Flynn, E. M.; Hewitt, M.; Huang, H.-R.; Kiefer, J. R.; Murray, J.; Nasveschuk, C. G.; Pardo, E.; Romero, F. A.; Sandy, P.; Tang, Y.; Taylor, A. M.; Tsui, V.; Wang, J.; Wang, S.; Zawadzke, L.; Albrecht, B. K.; Magnuson, S. R.; Cochran, A. G.; Stokoe, D. Bioorg. Med. Chem. Lett. 2017, 27, 3534. doi: 10.1016/j.bmcl.2017.05.063
41. [41]
  Ding, H.-W.; Deng, C.-L.; Li, D.-D.; Liu, D.-D.; Chai, S.-M.; Wang, W.; Zhang, Y.; Chen, K.; Li, X.; Wang, J.; Song, S.-J.; Song, H.-R. Eur. J. Med. Chem. 2018, 146, 460. doi: 10.1016/j.ejmech.2018.01.081
42. [42]
  Zhang, J.-K.; Lv, X.-Q.; Ma, X.-D.; Hu, Y.-Z. Eur. J. Med. Chem. 2017, 127, 509. doi: 10.1016/j.ejmech.2017.01.016
43. [43]
  Zhang, K.-H.; Lai, F.-F.; Lin, S.-W.; Ji, M.; Zhang, J.-B.; Zhang, Y.; Jin, J.; Fu, R.; Wu, D.-Y.; Tian, H.; Xue, N.-N.; Sheng, L.; Zou, X.-W.; Li, Y.; Chen, X.-G.; Xu, H. J. Med. Chem. 2019.
44. [44]
  Yao, L.-B.; Mustafa, N.; Tan, E. C.; Poulsen, A.; Singh, P.; Duong-Thi, M.-D.; Lee, J. X. T.; Ramanujulu, P. M.; Chng, W. J.; Yen, J. J. Y.; Ohlson, S.; Dymock, B. W. J. Med. Chem. 2017, 60, 8336. doi: 10.1021/acs.jmedchem.7b00678
1. [1]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
2. [2]
  Kun Zou , Yihang Xiao , Jinyu Yang , Mingxuan Wu . Facile semisynthesis of histone H3 enables nucleosome probes for investigation of histone H3K79 modifications. Chinese Chemical Letters, 2024, 35(10): 109497-. doi: 10.1016/j.cclet.2024.109497
3. [3]
  Xiongbo Song , Jinwen Xiao , Juan Wu , Li Sun , Long Chen . Decellularized amniotic membrane promotes the anti-inflammatory response of macrophages via PI3K/AKT/HIF-1α pathway. Chinese Chemical Letters, 2025, 36(1): 109844-. doi: 10.1016/j.cclet.2024.109844
4. [4]
  Jisheng Liu , Junli Chen , Xifeng Zhang , Yin Wu , Xin Qi , Jie Wang , Xiang Gao . Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment. Chinese Chemical Letters, 2024, 35(9): 109779-. doi: 10.1016/j.cclet.2024.109779
5. [5]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
6. [6]
  Run Chai , Qiujie Wu , Yongchao Liu , Xiaohui Song , Xuyong Feng , Yi Sun , Hongfa Xiang . A 3D dual layer host with enhanced sodiophilicity as stable anode for high-energy sodium metal batteries. Chinese Chemical Letters, 2025, 36(6): 110007-. doi: 10.1016/j.cclet.2024.110007
7. [7]
  Guangchang Yang , Shenglong Yang , Jinlian Yu , Yishun Xie , Chunlei Tan , Feiyan Lai , Qianqian Jin , Hongqiang Wang , Xiaohui Zhang . Regulating local chemical environment in O3-type layered sodium oxides by dual-site Mg²⁺/B³⁺ substitution achieves durable and high-rate cathode. Chinese Chemical Letters, 2024, 35(9): 109722-. doi: 10.1016/j.cclet.2024.109722
8. [8]
  Hong-Tao Ji , Yu-Han Lu , Yan-Ting Liu , Yu-Lin Huang , Jiang-Feng Tian , Feng Liu , Yan-Yan Zeng , Hai-Yan Yang , Yong-Hong Zhang , Wei-Min He . Nd@C₃N₄-photoredox/chlorine dual catalyzed synthesis and evaluation of antitumor activities of 4-alkylated sulfonyl ketimines. Chinese Chemical Letters, 2025, 36(2): 110568-. doi: 10.1016/j.cclet.2024.110568
9. [9]
  Gengchen Guo , Tianyu Zhao , Ruichang Sun , Mingzhe Song , Hongyu Liu , Sen Wang , Jingwen Li , Jingbin Zeng . Au-Fe₃O₄ dumbbell-like nanoparticles based lateral flow immunoassay for colorimetric and photothermal dual-mode detection of SARS-CoV-2 spike protein. Chinese Chemical Letters, 2024, 35(6): 109198-. doi: 10.1016/j.cclet.2023.109198
10. [10]
  Fei Yin , Erli Yang , Xue Ge , Qian Sun , Fan Mo , Guoqiu Wu , Yanfei Shen . Coupling WO₃₋_x dots-encapsulated metal-organic frameworks and template-free branched polymerization for dual signal-amplified electrochemiluminescence biosensing. Chinese Chemical Letters, 2024, 35(4): 108753-. doi: 10.1016/j.cclet.2023.108753
11. [11]
  Yuan Teng , Zichun Zhou , Jinghua Chen , Siying Huang , Hongyan Chen , Daibin Kuang . Dual atom-bridge effect promoting interfacial charge transfer in 2D/2D Cs₃Bi₂Br₉/BiOBr epitaxial heterojunction for efficient photocatalysis. Chinese Chemical Letters, 2025, 36(2): 110430-. doi: 10.1016/j.cclet.2024.110430
12. [12]
  Wei Zhong , Dan Zheng , Yuanxin Ou , Aiyun Meng , Yaorong Su . K原子掺杂高度面间结晶的g-C₃N₄光催化剂及其高效H₂O₂光合成. Acta Physico-Chimica Sinica, 2024, 40(11): 2406005-. doi: 10.3866/PKU.WHXB202406005
13. [13]
  Han Han , Bi-Te Chen , Jia-Rong Ding , Jin-Ming Si , Tian-Jiao Zhou , Yi Wang , Lei Xing , Hu-Lin Jiang . A PDGFRβ-targeting nanodrill system for pancreatic fibrosis therapy. Chinese Chemical Letters, 2024, 35(10): 109583-. doi: 10.1016/j.cclet.2024.109583
14. [14]
  Yiran Tao , Chunlei Dai , Zhaoxiang Xie , Xinru You , Kaiwen Li , Jun Wu , Hai Huang . Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer. Chinese Chemical Letters, 2024, 35(8): 109170-. doi: 10.1016/j.cclet.2023.109170
15. [15]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463
16. [16]
  Chao Chen , Wenwen Yu , Guangen Huang , Xuelian Ren , Xiangli Chen , Yixin Li , Shenggui Liang , Mengmeng Xu , Mingyue Zheng , Yaxi Yang , He Huang , Wei Tang , Bing Zhou . Asymmetric macrocyclization enabled by Rh(Ⅲ)-catalyzed CH activation: Enantioenriched macrocyclic inhibitor of Zika virus infection. Chinese Chemical Letters, 2024, 35(11): 109574-. doi: 10.1016/j.cclet.2024.109574
17. [17]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
18. [18]
  Zhexin Chen , Yuqing Shi , Fang Zhong , Kai Zhang , Furong Zhang , Shenghong Xie , Zhongbin Cheng , Qian Zhou , Yi-You Huang , Hai-Bin Luo . Discovery of amentoflavone as a natural PDE4 inhibitor with anti-fibrotic effects. Chinese Chemical Letters, 2025, 36(4): 109956-. doi: 10.1016/j.cclet.2024.109956
19. [19]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378
20. [20]
  Lu-Lu He , Lan-Tu Xiong , Xin Wang , Yu-Zhen Li , Jia-Bao Li , Yu Shi , Xin Deng , Zi-Ning Cui . Application of inhibitors targeting the type III secretion system in phytopathogenic bacteria. Chinese Chemical Letters, 2025, 36(4): 110044-. doi: 10.1016/j.cclet.2024.110044

Get Citation

PDF

XML

Metrics

PDF Downloads(10)
Abstract views(870)
HTML views(145)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142